Drug intelligence / Profile preview

RG-19 XX

Development stage: Preclinical
Lead developer: Hangzhou Ronggu Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

RG-19 XX (also known as RG-19XX) is a preclinical-stage, CD19-directed armored chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Hangzhou RonGu Biotechnology. Engineered using a lentiviral vector, the candidate is designed to co-express a nanobody or an armoring factor alongside the CD19-targeting CAR construct to enhance anti-tumor efficacy and overcome resistance mechanisms. It is primarily being developed for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (ALL).

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on RG-19 XX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-19 XX.

Explore the full profile